{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:52:17Z","timestamp":1785768737803,"version":"3.56.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Psychology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.copsyc.2025.102129","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:10:52Z","timestamp":1754493052000},"page":"102129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Between enhancement and risk: A critical review of psychedelic microdosing"],"prefix":"10.1016","volume":"66","author":[{"given":"Iva","family":"Totomanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline C.H.M.","family":"Haijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra P.M.","family":"Hurks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes G.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-3809","authenticated-orcid":false,"given":"Kim P.C.","family":"Kuypers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.copsyc.2025.102129_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.2023.2278586","article-title":"Efficacy and safety of four psychedelic-assisted therapies for adults with symptoms of depression, anxiety, and posttraumatic stress disorder: a systematic review and meta-analysis","volume":"57","author":"Bahji","year":"2025","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.copsyc.2025.102129_bib2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12954-019-0308-4","article-title":"Psychedelic microdosing benefits and challenges: an empirical codebook","volume":"16","author":"Anderson","year":"2019","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.copsyc.2025.102129_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0269881120953994","article-title":"Microdosing psychedelics: subjective benefits and challenges, substance testing behavior, and the relevance of intention","volume":"36","author":"Petranker","year":"2022","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.copsyc.2025.102129_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic microdosing: prevalence and subjective effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.copsyc.2025.102129_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fpsyt.2019.00672","article-title":"Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers","volume":"10","author":"Hutten","year":"2019","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2019.11.008","article-title":"Microdosing psychedelics: motivations, subjective effects and harm reduction","volume":"75","author":"Lea","year":"2020","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.copsyc.2025.102129_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211023","article-title":"A systematic study of microdosing psychedelics","volume":"14","author":"Polito","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.copsyc.2025.102129_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2022.101012","article-title":"Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: a prospective naturalistic study","volume":"1","author":"Haijen","year":"2022","journal-title":"Neurosci Appl"},{"key":"10.1016\/j.copsyc.2025.102129_bib10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","article-title":"Microdosing psilocybin for chronic pain: a case series","volume":"164","author":"Lyes","year":"2023","journal-title":"Pain"},{"key":"10.1016\/j.copsyc.2025.102129_bib11","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.copsyc.2025.102129_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/02791072.2019.1683260","article-title":"Psychedelic microdosing: a subreddit analysis","volume":"52","author":"Lea","year":"2020","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.copsyc.2025.102129_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12954-019-0333-3","article-title":"Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube","volume":"16","author":"Andersson","year":"2019","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.copsyc.2025.102129_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2024.1356496","article-title":"The rising use of cognitive enhancement drugs and predictors of use during COVID-19: findings from a cross-sectional survey of students and university staff in the UK","volume":"15","author":"Tully","year":"2024","journal-title":"Front Psychol"},{"key":"10.1016\/j.copsyc.2025.102129_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/02791072.2019.1593561","article-title":"Might microdosing psychedelics be safe and beneficial? An initial exploration","volume":"51","author":"Fadiman","year":"2019","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.copsyc.2025.102129_bib16","article-title":"Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls","volume":"12","author":"Rootman","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.copsyc.2025.102129_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/02698811211050556","article-title":"Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study","volume":"36","author":"Marschall","year":"2022","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62878","article-title":"Self-blinding citizen science to explore psychedelic microdosing","volume":"10","author":"Szigeti","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.copsyc.2025.102129_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13143","article-title":"Repeated low doses of LSD in healthy adults: a placebo-controlled, dose\u2013response study","volume":"27","author":"de Wit","year":"2022","journal-title":"Addict Biol"},{"key":"10.1016\/j.copsyc.2025.102129_bib20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/s41386-023-01772-4","article-title":"Greater subjective effects of a low dose of LSD in participants with depressed mood","volume":"49","author":"Molla","year":"2024","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib21","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00213-021-05991-9","article-title":"Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults","volume":"239","author":"Murray","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41386-022-01479-y","article-title":"Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity","volume":"48","author":"Glazer","year":"2023","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib24","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","article-title":"Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers","volume":"86","author":"Bershad","year":"2019","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euroneuro.2020.10.002","article-title":"Mood and cognition after administration of low LSD doses in healthy volunteers: a placebo controlled dose-effect finding study","volume":"41","author":"Hutten","year":"2020","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","article-title":"Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study","volume":"12","author":"Cavanna","year":"2022","journal-title":"Transl Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: impact on patient-reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J Affect Disord"},{"key":"10.1016\/j.copsyc.2025.102129_sref29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","article-title":"Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial","volume":"94","author":"Murphy","year":"2023","journal-title":"Biol Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/head.14837","article-title":"Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study","volume":"64","author":"Rucker","year":"2024","journal-title":"Headache"},{"key":"10.1016\/j.copsyc.2025.102129_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2008.02.006","article-title":"Effects of varied doses of psilocybin on time interval reproduction in human subjects","volume":"435","author":"Wackermann","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.copsyc.2025.102129_bib32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00213-018-5119-x","article-title":"The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial","volume":"236","author":"Yanakieva","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00213-018-5106-2","article-title":"Microdosing psychedelics: personality, mental health, and creativity differences in microdosers","volume":"236","author":"Anderson","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib34","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1007\/s00213-018-5049-7","article-title":"Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting","volume":"235","author":"Prochazkova","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00213-024-06680-z","article-title":"Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide","volume":"242","author":"Murphy","year":"2025","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib36","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-021-81446-7","article-title":"Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing","volume":"11","author":"Kaertner","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.copsyc.2025.102129_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/01459740.2022.2054716","article-title":"Subject in the making: technologies of the self and aspirations for a good life in contemporary Denmark","volume":"41","author":"Petersen","year":"2022","journal-title":"Med Anthropol"},{"key":"10.1016\/j.copsyc.2025.102129_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01811-4","article-title":"Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers","volume":"11","author":"Rootman","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.copsyc.2025.102129_bib39","first-page":"44","article-title":"Self-administration of psilocybin in the setting of treatment-resistant depression","volume":"19","author":"Lyons","year":"2022","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.copsyc.2025.102129_bib40","first-page":"109","article-title":"The effectiveness of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease: a case study","volume":"16","author":"Kinderlehrer","year":"2023","journal-title":"Int Med Case Rep J"},{"key":"10.1016\/j.copsyc.2025.102129_bib41","article-title":"Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: a naturalistic prospective comparison study","volume":"67","author":"Haijen","year":"2024","journal-title":"Eur Psychiatr J Assoc Eur Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/20494637221114962","article-title":"Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey","volume":"16","author":"Bonnelle","year":"2022","journal-title":"Br J Pain"},{"key":"10.1016\/j.copsyc.2025.102129_bib43","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00213-021-05857-0","article-title":"Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study","volume":"239","author":"van Elk","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/02791072.2022.2080616","article-title":"Psychedelic microdosing, mindfulness, and anxiety: a cross-sectional mediation study","volume":"55","author":"Hartong","year":"2023","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.copsyc.2025.102129_bib45","first-page":"461","article-title":"Preliminary report on the effects of a low dose of LSD on resting-state amygdala functional connectivity","volume":"5","author":"Bershad","year":"2020","journal-title":"Biol Psychiatr Cogn Neurosci Neuroimag"},{"key":"10.1016\/j.copsyc.2025.102129_bib46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0269881117731279","article-title":"Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors","volume":"32","author":"Griffiths","year":"2018","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.copsyc.2025.102129_bib47","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.copsyc.2025.102129_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-024-02900-4","article-title":"LSD increases sleep duration the night after microdosing","volume":"14","author":"Allen","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.copsyc.2025.102129_bib49","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.copsyc.2025.102129_bib50","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.copsyc.2025.102129_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1233585","article-title":"Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study","volume":"14","author":"Haijen","year":"2023","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib52","article-title":"Exploring the discourses around microdosing psychedelics within the r\/microdosing online community","volume":"347","author":"Pop","year":"1982","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.copsyc.2025.102129_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102857","article-title":"Ibogaine therapy for addiction: consumer views from online fora","volume":"83","author":"Barber","year":"2020","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.copsyc.2025.102129_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00213-020-05477-0","article-title":"Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders","volume":"237","author":"Lea","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib55","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/0269881120908004","article-title":"Microdosing psychedelics:dDemographics, practices, and psychiatric comorbidities","volume":"34","author":"Rosenbaum","year":"2020","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.copsyc.2025.102129_bib56","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ijnp\/pyz029","article-title":"Motives and side-effects of microdosing with psychedelics among users","volume":"22","author":"Hutten","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2025.0044","article-title":"Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomized clinical trial","author":"Mueller","year":"2025","journal-title":"JAMA Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib58","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ejp.2171","article-title":"Potential analgesic effects of psychedelics on select chronic pain conditions: a survey study","volume":"28","author":"Cavarra","year":"2024","journal-title":"Eur J Pain"},{"key":"10.1016\/j.copsyc.2025.102129_bib60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/head.14420","article-title":"Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Schindler","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.copsyc.2025.102129_bib61","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1007\/s00213-022-06249-8","article-title":"Set and setting in microdosing: an oft-overlooked principle","volume":"239","author":"Hartogsohn","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.copsyc.2025.102129_bib62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41398-024-03013-8","article-title":"Inter-individual variability in neural response to low doses of LSD","volume":"14","author":"Hutten","year":"2024","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.copsyc.2025.102129_bib63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/02698811231225609","article-title":"Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: comparison to known cardiotoxins","volume":"38","author":"Rouaud","year":"2024","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.copsyc.2025.102129_bib64","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1038\/s41380-023-02280-z","article-title":"Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats","volume":"28","author":"Kiilerich","year":"2023","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.copsyc.2025.102129_bib65","unstructured":"This study found that participants with higher levels of depressed mood reported significantly greater subjective effects (e.g., altered perception, emotional changes) after a low dose of LSD (13 \u03bcg) compared to those with lower mood scores. The results suggest that baseline mood may influence sensitivity to psychedelics, highlighting the need to consider individual mental health states when evaluating the effects and potential therapeutic use of microdosing."},{"key":"10.1016\/j.copsyc.2025.102129_bib66","unstructured":"This study showed that low doses of LSD (13 \u03bcg and 26 \u03bcg) increased brain activity in reward-related regions, such as the striatum, during a monetary reward task. The findings suggest that microdoses of LSD may enhance reward sensitivity, which could be relevant for treating mood disorders like depression, where reward processing is often impaired."},{"key":"10.1016\/j.copsyc.2025.102129_bib67","unstructured":"This randomized controlled trial found that microdoses of LSD (10 \u03bcg and 20 \u03bcg), taken at home by healthy volunteers, produced modest but significant acute increases in self-reported positive mood compared to placebo. The study provides controlled evidence that microdosing LSD can acutely enhance mood in non-clinical settings, supporting claims of its potential mood-elevating effects and helping to bridge the gap between anecdotal reports and experimental research."},{"key":"10.1016\/j.copsyc.2025.102129_bib68","unstructured":"This naturalistic prospective study found that adults with severe ADHD symptoms who microdosed psychedelics reported similar improvements in emotion regulation, empathy, and ADHD symptoms compared to those using conventional ADHD medication. The findings suggest that psychedelic microdosing may offer comparable subjective benefits to standard ADHD treatments, highlighting the need for further controlled research into its therapeutic potential and safety in clinical populations."},{"key":"10.1016\/j.copsyc.2025.102129_bib69","unstructured":"This randomized clinical trial found that repeated low doses of LSD (20 \u03bcg, twice weekly for four weeks) were well tolerated but did not significantly reduce ADHD symptoms compared to placebo in adults. The study provides the first placebo-controlled evidence on repeated LSD microdosing for ADHD, suggesting limited efficacy despite good tolerability, and underscores the need for further research to clarify its therapeutic value."},{"key":"10.1016\/j.copsyc.2025.102129_bib70","unstructured":"This review compared psychedelics commonly used in microdosing (particularly LSD and psilocybin) with known cardiotoxic substances and found that some serotonergic psychedelics may pose a theoretical risk of cardiac fibrosis and valvulopathy through 5-HT2B receptor activation. The findings raise important safety concerns about chronic microdosing, especially with substances that act on 5-HT2B receptors, highlighting the need for long-term safety monitoring in future clinical and observational studies."}],"container-title":["Current Opinion in Psychology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352250X25001423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352250X25001423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:53:27Z","timestamp":1757620407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352250X25001423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":70,"alternative-id":["S2352250X25001423"],"URL":"https:\/\/doi.org\/10.1016\/j.copsyc.2025.102129","relation":{},"ISSN":["2352-250X"],"issn-type":[{"value":"2352-250X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Between enhancement and risk: A critical review of psychedelic microdosing","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Psychology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.copsyc.2025.102129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102129"}}